Friday, 16 October 2026European Markets

EBUSCO HOLDING Stock Drops By 27% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of EBUSCO HOLDING (AEX-Index: EBUS.AS) fell by a staggering 27.12% in 21 sessions from €12.61 to €9.19 at 02:12 EST on Monday, after two successive sessions in a row of gains. AEX-Index is rising 0.54% to €759.84, following the last session's upward trend.

EBUSCO HOLDING's last close was €9.19, 63.68% under its 52-week high of €25.30.

About EBUSCO HOLDING

Ebusco Holding N.V., together with its subsidiaries, develops, manufactures, and distributes zero emission buses, batteries, and charging systems in the Netherlands, Belgium, France, Germany, Norway, Switzerland, and Denmark. It also sells ancillary products and services; and provides electric vehicle ecosystem repair and maintenance services. Ebusco Holding N.V. was founded in 2010 and is headquartered in Deurne, the Netherlands.

Earnings Per Share

As for profitability, EBUSCO HOLDING has a trailing twelve months EPS of €322.07.

PE Ratio

EBUSCO HOLDING has a trailing twelve months price to earnings ratio of 0.03. Meaning, the purchaser of the share is investing €0.03 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -11.15%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 290.3%, now sitting on 111.62M for the twelve trailing months.

Moving Average

EBUSCO HOLDING's worth is way below its 50-day moving average of €12.25 and way under its 200-day moving average of €16.45.

Volatility

EBUSCO HOLDING's last week, last month's, and last quarter's current intraday variation average was a negative 0.91%, a negative 2.44%, and a positive 2.27%.

EBUSCO HOLDING's highest amplitude of average volatility was 1.68% (last week), 4.63% (last month), and 2.27% (last quarter).

Volume

Today's last reported volume for EBUSCO HOLDING is 98233 which is 38.08% below its average volume of 158607.

More news about EBUSCO HOLDING (EBUS.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com